Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionHepaticNotch1 floxed crossed with LysM-Cre to give myeloid-specific Notch1 knockout, with floxed littermate controlsIntravenous (JAG1 and siRNA with mannose-conjugated polymers; macrophages by tail vein)Recombinant JAG1 0.5 mg/kg; Snail or nonspecific siRNA 2 mg…JAG1 1 h before ischaemia; siRNA 4 h before ischaemia; macrophage adoptive tran…
Model: Warm hepatic ischaemia/reperfusion injury; atraumatic clip occluding arterial and portal venous supply to cephalad liver lobes for 90 minutes of ischaemia followed by 6 hours of reperfusion
JAG1 significantly reduced serum ALT and Suzuki histological injury scores in Notch1-proficient mice relative to PBS controls, with less oedema and sinusoidal congestion, lower myeloperoxidase and lower pro-inflammatory gene expression. Treated livers showed increased NICD, HSF1, Snail and TRX1 wit…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.86. Machine-extracted fields require source verification.